JP2019535825A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019535825A5 JP2019535825A5 JP2019547227A JP2019547227A JP2019535825A5 JP 2019535825 A5 JP2019535825 A5 JP 2019535825A5 JP 2019547227 A JP2019547227 A JP 2019547227A JP 2019547227 A JP2019547227 A JP 2019547227A JP 2019535825 A5 JP2019535825 A5 JP 2019535825A5
- Authority
- JP
- Japan
- Prior art keywords
- decane
- ethyl
- azaspiro
- oxa
- piperazine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 piperazine-1-yl Chemical group 0.000 claims description 158
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 92
- 125000000217 alkyl group Chemical group 0.000 claims description 84
- 150000001875 compounds Chemical class 0.000 claims description 47
- JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Chemical compound N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 claims description 36
- 229940002612 prodrug Drugs 0.000 claims description 36
- 239000000651 prodrug Substances 0.000 claims description 36
- 150000003839 salts Chemical class 0.000 claims description 36
- 239000012453 solvate Substances 0.000 claims description 36
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 32
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims description 30
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 30
- KSMVZQYAVGTKIV-UHFFFAOYSA-N decanal Chemical compound CCCCCCCCCC=O KSMVZQYAVGTKIV-UHFFFAOYSA-N 0.000 claims description 29
- 229910052799 carbon Inorganic materials 0.000 claims description 22
- YRCGAHTZOXPQPR-UHFFFAOYSA-N 2-ethylnonanoic acid Chemical compound CCCCCCCC(CC)C(O)=O YRCGAHTZOXPQPR-UHFFFAOYSA-N 0.000 claims description 18
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 15
- VFLQCKVZBDPECH-FQEVSTJZSA-N (3R)-3-[2-[4-(4-methoxyphenyl)piperazin-1-yl]ethyl]-8-methylsulfonyl-2-oxa-8-azaspiro[4.5]decan-1-one Chemical compound COC1=CC=C(C=C1)N1CCN(CC1)CC[C@@H]1OC(C2(C1)CCN(CC2)S(=O)(=O)C)=O VFLQCKVZBDPECH-FQEVSTJZSA-N 0.000 claims description 12
- VFLQCKVZBDPECH-HXUWFJFHSA-N (3S)-3-[2-[4-(4-methoxyphenyl)piperazin-1-yl]ethyl]-8-methylsulfonyl-2-oxa-8-azaspiro[4.5]decan-1-one Chemical compound COC1=CC=C(C=C1)N1CCN(CC1)CC[C@H]1OC(C2(C1)CCN(CC2)S(=O)(=O)C)=O VFLQCKVZBDPECH-HXUWFJFHSA-N 0.000 claims description 12
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 12
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims description 10
- 208000002193 Pain Diseases 0.000 claims description 8
- 208000035475 disorder Diseases 0.000 claims description 8
- 125000001188 haloalkyl group Chemical group 0.000 claims description 8
- 201000010099 disease Diseases 0.000 claims description 7
- JATPKJKMOVOWTJ-KRWDZBQOSA-N (3R)-3-[2-(3,4-dihydro-1H-isoquinolin-2-yl)ethyl]-2-oxa-8-azaspiro[4.5]decan-1-one Chemical compound C1N(CCC2=CC=CC=C12)CC[C@@H]1OC(C2(C1)CCNCC2)=O JATPKJKMOVOWTJ-KRWDZBQOSA-N 0.000 claims description 6
- MSGHYIDKBULJMQ-SFHVURJKSA-N (3R)-3-[2-(3,4-dihydro-1H-isoquinolin-2-yl)ethyl]-8-methylsulfonyl-2-oxa-8-azaspiro[4.5]decan-1-one Chemical compound C1N(CCC2=CC=CC=C12)CC[C@@H]1OC(C2(C1)CCN(CC2)S(=O)(=O)C)=O MSGHYIDKBULJMQ-SFHVURJKSA-N 0.000 claims description 6
- LVEFDAMYUHHQHJ-SFHVURJKSA-N (3R)-3-[2-(4-phenylpiperazin-1-yl)ethyl]-2,8-dioxaspiro[4.5]decan-1-one Chemical compound C1(=CC=CC=C1)N1CCN(CC1)CC[C@@H]1OC(C2(C1)CCOCC2)=O LVEFDAMYUHHQHJ-SFHVURJKSA-N 0.000 claims description 6
- DWSVKSNIDKVXAT-SFHVURJKSA-N (3R)-3-[2-[4-(2-methyl-1H-benzimidazol-4-yl)piperazin-1-yl]ethyl]-8-methylsulfonyl-2-oxa-8-azaspiro[4.5]decan-1-one Chemical compound CC1=NC2=C(N1)C(=CC=C2)N1CCN(CC1)CC[C@@H]1OC(C2(C1)CCN(CC2)S(=O)(=O)C)=O DWSVKSNIDKVXAT-SFHVURJKSA-N 0.000 claims description 6
- DYLOBGVCXUVCDQ-IBGZPJMESA-N (3R)-3-[2-[4-(2-propan-2-ylphenyl)piperazin-1-yl]ethyl]-2-oxa-8-azaspiro[4.5]decan-1-one Chemical compound C(C)(C)C1=C(C=CC=C1)N1CCN(CC1)CC[C@@H]1OC(C2(C1)CCNCC2)=O DYLOBGVCXUVCDQ-IBGZPJMESA-N 0.000 claims description 6
- NLRPHTYPVQBVTM-IBGZPJMESA-N (3R)-3-[2-[4-(4-chlorophenyl)piperazin-1-yl]ethyl]-8-methylsulfonyl-2-oxa-8-azaspiro[4.5]decan-1-one Chemical compound ClC1=CC=C(C=C1)N1CCN(CC1)CC[C@@H]1OC(C2(C1)CCN(CC2)S(=O)(=O)C)=O NLRPHTYPVQBVTM-IBGZPJMESA-N 0.000 claims description 6
- XUOWOSJIOQXTHR-IBGZPJMESA-N (3R)-3-[2-[4-(4-fluorophenyl)piperazin-1-yl]ethyl]-8-methylsulfonyl-2-oxa-8-azaspiro[4.5]decan-1-one Chemical compound FC1=CC=C(C=C1)N1CCN(CC1)CC[C@@H]1OC(C2(C1)CCN(CC2)S(=O)(=O)C)=O XUOWOSJIOQXTHR-IBGZPJMESA-N 0.000 claims description 6
- DBNZOMHCFYYUFH-SFHVURJKSA-N (3R)-3-[2-[4-(4-hydroxyphenyl)piperazin-1-yl]ethyl]-2,8-dioxaspiro[4.5]decan-1-one Chemical compound OC1=CC=C(C=C1)N1CCN(CC1)CC[C@@H]1OC(C2(C1)CCOCC2)=O DBNZOMHCFYYUFH-SFHVURJKSA-N 0.000 claims description 6
- GYYVGYZHBSQYSA-IBGZPJMESA-N (3R)-3-[2-[4-(4-iodophenyl)piperazin-1-yl]ethyl]-8-methylsulfonyl-2-oxa-8-azaspiro[4.5]decan-1-one Chemical compound IC1=CC=C(C=C1)N1CCN(CC1)CC[C@@H]1OC(C2(C1)CCN(CC2)S(=O)(=O)C)=O GYYVGYZHBSQYSA-IBGZPJMESA-N 0.000 claims description 6
- GEROZKBIIKZJQD-IBGZPJMESA-N (3R)-3-[2-[4-(4-methylphenyl)piperazin-1-yl]ethyl]-1-oxo-2-oxa-8-azaspiro[4.5]decane-8-carboxylic acid Chemical compound CC1=CC=C(C=C1)N2CCN(CC2)CC[C@H]3CC4(CCN(CC4)C(=O)O)C(=O)O3 GEROZKBIIKZJQD-IBGZPJMESA-N 0.000 claims description 6
- AOQMTPLAFACCAA-IBGZPJMESA-N (3R)-3-[2-[4-(4-methylphenyl)piperazin-1-yl]ethyl]-2-oxa-8-azaspiro[4.5]decan-1-one Chemical compound C1(=CC=C(C=C1)N1CCN(CC1)CC[C@@H]1OC(C2(C1)CCNCC2)=O)C AOQMTPLAFACCAA-IBGZPJMESA-N 0.000 claims description 6
- VJBPXHGLMVAHSC-QFIPXVFZSA-N (3R)-3-[2-[4-(4-methylphenyl)piperazin-1-yl]ethyl]-8-(1-methylpyrazol-4-yl)sulfonyl-2-oxa-8-azaspiro[4.5]decan-1-one Chemical compound CN1N=CC(=C1)S(=O)(=O)N1CCC2(C[C@@H](OC2=O)CCN2CCN(CC2)C2=CC=C(C=C2)C)CC1 VJBPXHGLMVAHSC-QFIPXVFZSA-N 0.000 claims description 6
- RFVGDDCWNZROBF-QHCPKHFHSA-N (3R)-3-[2-[4-(4-methylphenyl)piperazin-1-yl]ethyl]-8-(2-methylpropylsulfonyl)-2-oxa-8-azaspiro[4.5]decan-1-one Chemical compound C(C(C)C)S(=O)(=O)N1CCC2(C[C@@H](OC2=O)CCN2CCN(CC2)C2=CC=C(C=C2)C)CC1 RFVGDDCWNZROBF-QHCPKHFHSA-N 0.000 claims description 6
- PPYWCSCCCMLOJK-NRFANRHFSA-N (3R)-3-[2-[4-(4-methylphenyl)piperazin-1-yl]ethyl]-8-(3,3,3-trifluoropropylsulfonyl)-2-oxa-8-azaspiro[4.5]decan-1-one Chemical compound C1(=CC=C(C=C1)N1CCN(CC1)CC[C@@H]1OC(C2(C1)CCN(CC2)S(=O)(=O)CCC(F)(F)F)=O)C PPYWCSCCCMLOJK-NRFANRHFSA-N 0.000 claims description 6
- IBCZAESGPAEFDR-NRFANRHFSA-N (3R)-3-[2-[4-(4-methylphenyl)piperazin-1-yl]ethyl]-8-(methylsulfonylmethylsulfonyl)-2-oxa-8-azaspiro[4.5]decan-1-one Chemical compound CS(=O)(=O)CS(=O)(=O)N1CCC2(C[C@@H](OC2=O)CCN2CCN(CC2)C2=CC=C(C=C2)C)CC1 IBCZAESGPAEFDR-NRFANRHFSA-N 0.000 claims description 6
- HAABJSKHNYVPIS-FQEVSTJZSA-N (3R)-3-[2-[4-(4-methylphenyl)piperazin-1-yl]ethyl]-8-methylsulfonyl-2-oxa-8-azaspiro[4.5]decan-1-one Chemical compound CS(=O)(=O)N1CCC2(C[C@@H](OC2=O)CCN2CCN(CC2)C2=CC=C(C=C2)C)CC1 HAABJSKHNYVPIS-FQEVSTJZSA-N 0.000 claims description 6
- XRAXHGOJXJICHV-QFIPXVFZSA-N (3R)-3-[2-[4-(4-methylphenyl)piperazin-1-yl]ethyl]-8-propan-2-ylsulfonyl-2-oxa-8-azaspiro[4.5]decan-1-one Chemical compound C(C)(C)S(=O)(=O)N1CCC2(C[C@@H](OC2=O)CCN2CCN(CC2)C2=CC=C(C=C2)C)CC1 XRAXHGOJXJICHV-QFIPXVFZSA-N 0.000 claims description 6
- FQKXMSNIIBZBSZ-NRFANRHFSA-N (3R)-8-(1H-imidazol-5-ylsulfonyl)-3-[2-[4-(4-methylphenyl)piperazin-1-yl]ethyl]-2-oxa-8-azaspiro[4.5]decan-1-one Chemical compound N1C=NC(=C1)S(=O)(=O)N1CCC2(C[C@@H](OC2=O)CCN2CCN(CC2)C2=CC=C(C=C2)C)CC1 FQKXMSNIIBZBSZ-NRFANRHFSA-N 0.000 claims description 6
- SVLHYKSKWDHJTK-DEOSSOPVSA-N (3R)-8-(benzenesulfonyl)-3-[2-[4-(4-methylphenyl)piperazin-1-yl]ethyl]-2-oxa-8-azaspiro[4.5]decan-1-one Chemical compound C1(=CC=CC=C1)S(=O)(=O)N1CCC2(C[C@@H](OC2=O)CCN2CCN(CC2)C2=CC=C(C=C2)C)CC1 SVLHYKSKWDHJTK-DEOSSOPVSA-N 0.000 claims description 6
- HCALZOPJVCEXCO-NRFANRHFSA-N (3R)-8-acetyl-3-[2-[4-(4-methylphenyl)piperazin-1-yl]ethyl]-2-oxa-8-azaspiro[4.5]decan-1-one Chemical compound C(C)(=O)N1CCC2(C[C@@H](OC2=O)CCN2CCN(CC2)C2=CC=C(C=C2)C)CC1 HCALZOPJVCEXCO-NRFANRHFSA-N 0.000 claims description 6
- QWTRNVUDPLLEAB-SANMLTNESA-N (3R)-8-benzyl-3-[2-[4-(4-methylphenyl)piperazin-1-yl]ethyl]-2-oxa-8-azaspiro[4.5]decan-1-one Chemical compound C(C1=CC=CC=C1)N1CCC2(C[C@@H](OC2=O)CCN2CCN(CC2)C2=CC=C(C=C2)C)CC1 QWTRNVUDPLLEAB-SANMLTNESA-N 0.000 claims description 6
- KDOXPDDODOMYHZ-DEOSSOPVSA-N (3R)-8-cyclohexylsulfonyl-3-[2-[4-(4-methylphenyl)piperazin-1-yl]ethyl]-2-oxa-8-azaspiro[4.5]decan-1-one Chemical compound C1(CCCCC1)S(=O)(=O)N1CCC2(C[C@@H](OC2=O)CCN2CCN(CC2)C2=CC=C(C=C2)C)CC1 KDOXPDDODOMYHZ-DEOSSOPVSA-N 0.000 claims description 6
- FEBDLPMJOFFKLE-QHCPKHFHSA-N (3R)-8-cyclopentylsulfonyl-3-[2-[4-(4-methylphenyl)piperazin-1-yl]ethyl]-2-oxa-8-azaspiro[4.5]decan-1-one Chemical compound C1(CCCC1)S(=O)(=O)N1CCC2(C[C@@H](OC2=O)CCN2CCN(CC2)C2=CC=C(C=C2)C)CC1 FEBDLPMJOFFKLE-QHCPKHFHSA-N 0.000 claims description 6
- JJEZISOSFDGULR-NRFANRHFSA-N (3R)-8-cyclopropylsulfonyl-3-[2-[4-(4-methylphenyl)piperazin-1-yl]ethyl]-2-oxa-8-azaspiro[4.5]decan-1-one Chemical compound C1(CC1)S(=O)(=O)N1CCC2(C[C@@H](OC2=O)CCN2CCN(CC2)C2=CC=C(C=C2)C)CC1 JJEZISOSFDGULR-NRFANRHFSA-N 0.000 claims description 6
- LTLWVHRDJYSFHE-NRFANRHFSA-N (3R)-8-ethylsulfonyl-3-[2-[4-(4-methylphenyl)piperazin-1-yl]ethyl]-2-oxa-8-azaspiro[4.5]decan-1-one Chemical compound C(C)S(=O)(=O)N1CCC2(C[C@@H](OC2=O)CCN2CCN(CC2)C2=CC=C(C=C2)C)CC1 LTLWVHRDJYSFHE-NRFANRHFSA-N 0.000 claims description 6
- IONUVCVGGHEYJY-IBGZPJMESA-N (3R)-8-methylsulfonyl-3-[2-[4-(4-nitrophenyl)piperazin-1-yl]ethyl]-2-oxa-8-azaspiro[4.5]decan-1-one Chemical compound CS(=O)(=O)N1CCC2(C[C@@H](OC2=O)CCN2CCN(CC2)C2=CC=C(C=C2)[N+](=O)[O-])CC1 IONUVCVGGHEYJY-IBGZPJMESA-N 0.000 claims description 6
- JATPKJKMOVOWTJ-QGZVFWFLSA-N (3S)-3-[2-(3,4-dihydro-1H-isoquinolin-2-yl)ethyl]-2-oxa-8-azaspiro[4.5]decan-1-one Chemical compound C1N(CCC2=CC=CC=C12)CC[C@H]1OC(C2(C1)CCNCC2)=O JATPKJKMOVOWTJ-QGZVFWFLSA-N 0.000 claims description 6
- MSGHYIDKBULJMQ-GOSISDBHSA-N (3S)-3-[2-(3,4-dihydro-1H-isoquinolin-2-yl)ethyl]-8-methylsulfonyl-2-oxa-8-azaspiro[4.5]decan-1-one Chemical compound C1N(CCC2=CC=CC=C12)CC[C@H]1OC(C2(C1)CCN(CC2)S(=O)(=O)C)=O MSGHYIDKBULJMQ-GOSISDBHSA-N 0.000 claims description 6
- LVEFDAMYUHHQHJ-GOSISDBHSA-N (3S)-3-[2-(4-phenylpiperazin-1-yl)ethyl]-2,8-dioxaspiro[4.5]decan-1-one Chemical compound C1(=CC=CC=C1)N1CCN(CC1)CC[C@H]1OC(C2(C1)CCOCC2)=O LVEFDAMYUHHQHJ-GOSISDBHSA-N 0.000 claims description 6
- DWSVKSNIDKVXAT-GOSISDBHSA-N (3S)-3-[2-[4-(2-methyl-1H-benzimidazol-4-yl)piperazin-1-yl]ethyl]-8-methylsulfonyl-2-oxa-8-azaspiro[4.5]decan-1-one Chemical compound CC1=NC2=C(N1)C(=CC=C2)N1CCN(CC1)CC[C@H]1OC(C2(C1)CCN(CC2)S(=O)(=O)C)=O DWSVKSNIDKVXAT-GOSISDBHSA-N 0.000 claims description 6
- DYLOBGVCXUVCDQ-LJQANCHMSA-N (3S)-3-[2-[4-(2-propan-2-ylphenyl)piperazin-1-yl]ethyl]-2-oxa-8-azaspiro[4.5]decan-1-one Chemical compound C(C)(C)C1=C(C=CC=C1)N1CCN(CC1)CC[C@H]1OC(C2(C1)CCNCC2)=O DYLOBGVCXUVCDQ-LJQANCHMSA-N 0.000 claims description 6
- NLRPHTYPVQBVTM-LJQANCHMSA-N (3S)-3-[2-[4-(4-chlorophenyl)piperazin-1-yl]ethyl]-8-methylsulfonyl-2-oxa-8-azaspiro[4.5]decan-1-one Chemical compound ClC1=CC=C(C=C1)N1CCN(CC1)CC[C@H]1OC(C2(C1)CCN(CC2)S(=O)(=O)C)=O NLRPHTYPVQBVTM-LJQANCHMSA-N 0.000 claims description 6
- XUOWOSJIOQXTHR-LJQANCHMSA-N (3S)-3-[2-[4-(4-fluorophenyl)piperazin-1-yl]ethyl]-8-methylsulfonyl-2-oxa-8-azaspiro[4.5]decan-1-one Chemical compound FC1=CC=C(C=C1)N1CCN(CC1)CC[C@H]1OC(C2(C1)CCN(CC2)S(=O)(=O)C)=O XUOWOSJIOQXTHR-LJQANCHMSA-N 0.000 claims description 6
- DBNZOMHCFYYUFH-GOSISDBHSA-N (3S)-3-[2-[4-(4-hydroxyphenyl)piperazin-1-yl]ethyl]-2,8-dioxaspiro[4.5]decan-1-one Chemical compound OC1=CC=C(C=C1)N1CCN(CC1)CC[C@H]1OC(C2(C1)CCOCC2)=O DBNZOMHCFYYUFH-GOSISDBHSA-N 0.000 claims description 6
- GYYVGYZHBSQYSA-LJQANCHMSA-N (3S)-3-[2-[4-(4-iodophenyl)piperazin-1-yl]ethyl]-8-methylsulfonyl-2-oxa-8-azaspiro[4.5]decan-1-one Chemical compound IC1=CC=C(C=C1)N1CCN(CC1)CC[C@H]1OC(C2(C1)CCN(CC2)S(=O)(=O)C)=O GYYVGYZHBSQYSA-LJQANCHMSA-N 0.000 claims description 6
- GEROZKBIIKZJQD-LJQANCHMSA-N (3S)-3-[2-[4-(4-methylphenyl)piperazin-1-yl]ethyl]-1-oxo-2-oxa-8-azaspiro[4.5]decane-8-carboxylic acid Chemical compound CC1=CC=C(C=C1)N2CCN(CC2)CC[C@@H]3CC4(CCN(CC4)C(=O)O)C(=O)O3 GEROZKBIIKZJQD-LJQANCHMSA-N 0.000 claims description 6
- AOQMTPLAFACCAA-LJQANCHMSA-N (3S)-3-[2-[4-(4-methylphenyl)piperazin-1-yl]ethyl]-2-oxa-8-azaspiro[4.5]decan-1-one Chemical compound C1(=CC=C(C=C1)N1CCN(CC1)CC[C@H]1OC(C2(C1)CCNCC2)=O)C AOQMTPLAFACCAA-LJQANCHMSA-N 0.000 claims description 6
- RFVGDDCWNZROBF-HSZRJFAPSA-N (3S)-3-[2-[4-(4-methylphenyl)piperazin-1-yl]ethyl]-8-(2-methylpropylsulfonyl)-2-oxa-8-azaspiro[4.5]decan-1-one Chemical compound CC(C)CS(=O)(=O)N1CCC2(C[C@@H](CCN3CCN(CC3)c3ccc(C)cc3)OC2=O)CC1 RFVGDDCWNZROBF-HSZRJFAPSA-N 0.000 claims description 6
- PPYWCSCCCMLOJK-OAQYLSRUSA-N (3S)-3-[2-[4-(4-methylphenyl)piperazin-1-yl]ethyl]-8-(3,3,3-trifluoropropylsulfonyl)-2-oxa-8-azaspiro[4.5]decan-1-one Chemical compound C1(=CC=C(C=C1)N1CCN(CC1)CC[C@H]1OC(C2(C1)CCN(CC2)S(=O)(=O)CCC(F)(F)F)=O)C PPYWCSCCCMLOJK-OAQYLSRUSA-N 0.000 claims description 6
- IBCZAESGPAEFDR-OAQYLSRUSA-N (3S)-3-[2-[4-(4-methylphenyl)piperazin-1-yl]ethyl]-8-(methylsulfonylmethylsulfonyl)-2-oxa-8-azaspiro[4.5]decan-1-one Chemical compound CS(=O)(=O)CS(=O)(=O)N1CCC2(C[C@H](OC2=O)CCN2CCN(CC2)C2=CC=C(C=C2)C)CC1 IBCZAESGPAEFDR-OAQYLSRUSA-N 0.000 claims description 6
- RJOLIGKCRQYQOL-HSZRJFAPSA-N (3S)-3-[2-[4-(4-methylphenyl)piperazin-1-yl]ethyl]-8-(oxan-4-ylsulfonyl)-2-oxa-8-azaspiro[4.5]decan-1-one Chemical compound O1CCC(CC1)S(=O)(=O)N1CCC2(C[C@H](OC2=O)CCN2CCN(CC2)C2=CC=C(C=C2)C)CC1 RJOLIGKCRQYQOL-HSZRJFAPSA-N 0.000 claims description 6
- COMNXBZKDGZNBB-LJQANCHMSA-N (3S)-3-[2-[4-(4-methylphenyl)piperazin-1-yl]ethyl]-8-(trifluoromethylsulfonyl)-2-oxa-8-azaspiro[4.5]decan-1-one Chemical compound Cc1ccc(cc1)N1CCN(CC[C@@H]2CC3(CCN(CC3)S(=O)(=O)C(F)(F)F)C(=O)O2)CC1 COMNXBZKDGZNBB-LJQANCHMSA-N 0.000 claims description 6
- HAABJSKHNYVPIS-HXUWFJFHSA-N (3S)-3-[2-[4-(4-methylphenyl)piperazin-1-yl]ethyl]-8-methylsulfonyl-2-oxa-8-azaspiro[4.5]decan-1-one Chemical compound CS(=O)(=O)N1CCC2(C[C@H](OC2=O)CCN2CCN(CC2)C2=CC=C(C=C2)C)CC1 HAABJSKHNYVPIS-HXUWFJFHSA-N 0.000 claims description 6
- XRAXHGOJXJICHV-JOCHJYFZSA-N (3S)-3-[2-[4-(4-methylphenyl)piperazin-1-yl]ethyl]-8-propan-2-ylsulfonyl-2-oxa-8-azaspiro[4.5]decan-1-one Chemical compound C(C)(C)S(=O)(=O)N1CCC2(C[C@H](OC2=O)CCN2CCN(CC2)C2=CC=C(C=C2)C)CC1 XRAXHGOJXJICHV-JOCHJYFZSA-N 0.000 claims description 6
- LWWQWOBMASADIS-JOCHJYFZSA-N (3S)-3-[2-[4-(4-methylphenyl)piperazin-1-yl]ethyl]-8-propylsulfonyl-2-oxa-8-azaspiro[4.5]decan-1-one Chemical compound CCCS(=O)(=O)N1CCC2(C[C@@H](CCN3CCN(CC3)c3ccc(C)cc3)OC2=O)CC1 LWWQWOBMASADIS-JOCHJYFZSA-N 0.000 claims description 6
- RNPKANUIEAXNOT-HSZRJFAPSA-N (3S)-3-[2-[4-(4-methylphenyl)piperazin-1-yl]ethyl]-8-pyridin-3-ylsulfonyl-2-oxa-8-azaspiro[4.5]decan-1-one Chemical compound N1=CC(=CC=C1)S(=O)(=O)N1CCC2(C[C@H](OC2=O)CCN2CCN(CC2)C2=CC=C(C=C2)C)CC1 RNPKANUIEAXNOT-HSZRJFAPSA-N 0.000 claims description 6
- CBZZOTNOZBEVQI-XMMPIXPASA-N (3S)-8-(4-chlorophenyl)sulfonyl-3-[2-[4-(4-methylphenyl)piperazin-1-yl]ethyl]-2-oxa-8-azaspiro[4.5]decan-1-one Chemical compound ClC1=CC=C(C=C1)S(=O)(=O)N1CCC2(C[C@H](OC2=O)CCN2CCN(CC2)C2=CC=C(C=C2)C)CC1 CBZZOTNOZBEVQI-XMMPIXPASA-N 0.000 claims description 6
- GYKAZPZXLMTMCZ-RUZDIDTESA-N (3S)-8-(4-methoxyphenyl)sulfonyl-3-[2-[4-(4-methylphenyl)piperazin-1-yl]ethyl]-2-oxa-8-azaspiro[4.5]decan-1-one Chemical compound COc1ccc(cc1)S(=O)(=O)N1CCC2(C[C@@H](CCN3CCN(CC3)c3ccc(C)cc3)OC2=O)CC1 GYKAZPZXLMTMCZ-RUZDIDTESA-N 0.000 claims description 6
- SVLHYKSKWDHJTK-XMMPIXPASA-N (3S)-8-(benzenesulfonyl)-3-[2-[4-(4-methylphenyl)piperazin-1-yl]ethyl]-2-oxa-8-azaspiro[4.5]decan-1-one Chemical compound C1(=CC=CC=C1)S(=O)(=O)N1CCC2(C[C@H](OC2=O)CCN2CCN(CC2)C2=CC=C(C=C2)C)CC1 SVLHYKSKWDHJTK-XMMPIXPASA-N 0.000 claims description 6
- HCALZOPJVCEXCO-OAQYLSRUSA-N (3S)-8-acetyl-3-[2-[4-(4-methylphenyl)piperazin-1-yl]ethyl]-2-oxa-8-azaspiro[4.5]decan-1-one Chemical compound C(C)(=O)N1CCC2(C[C@H](OC2=O)CCN2CCN(CC2)C2=CC=C(C=C2)C)CC1 HCALZOPJVCEXCO-OAQYLSRUSA-N 0.000 claims description 6
- QWTRNVUDPLLEAB-AREMUKBSSA-N (3S)-8-benzyl-3-[2-[4-(4-methylphenyl)piperazin-1-yl]ethyl]-2-oxa-8-azaspiro[4.5]decan-1-one Chemical compound C(C1=CC=CC=C1)N1CCC2(C[C@H](OC2=O)CCN2CCN(CC2)C2=CC=C(C=C2)C)CC1 QWTRNVUDPLLEAB-AREMUKBSSA-N 0.000 claims description 6
- KDOXPDDODOMYHZ-XMMPIXPASA-N (3S)-8-cyclohexylsulfonyl-3-[2-[4-(4-methylphenyl)piperazin-1-yl]ethyl]-2-oxa-8-azaspiro[4.5]decan-1-one Chemical compound C1(CCCCC1)S(=O)(=O)N1CCC2(C[C@H](OC2=O)CCN2CCN(CC2)C2=CC=C(C=C2)C)CC1 KDOXPDDODOMYHZ-XMMPIXPASA-N 0.000 claims description 6
- FEBDLPMJOFFKLE-HSZRJFAPSA-N (3S)-8-cyclopentylsulfonyl-3-[2-[4-(4-methylphenyl)piperazin-1-yl]ethyl]-2-oxa-8-azaspiro[4.5]decan-1-one Chemical compound C1(CCCC1)S(=O)(=O)N1CCC2(C[C@H](OC2=O)CCN2CCN(CC2)C2=CC=C(C=C2)C)CC1 FEBDLPMJOFFKLE-HSZRJFAPSA-N 0.000 claims description 6
- JJEZISOSFDGULR-OAQYLSRUSA-N (3S)-8-cyclopropylsulfonyl-3-[2-[4-(4-methylphenyl)piperazin-1-yl]ethyl]-2-oxa-8-azaspiro[4.5]decan-1-one Chemical compound C1(CC1)S(=O)(=O)N1CCC2(C[C@H](OC2=O)CCN2CCN(CC2)C2=CC=C(C=C2)C)CC1 JJEZISOSFDGULR-OAQYLSRUSA-N 0.000 claims description 6
- LTLWVHRDJYSFHE-OAQYLSRUSA-N (3S)-8-ethylsulfonyl-3-[2-[4-(4-methylphenyl)piperazin-1-yl]ethyl]-2-oxa-8-azaspiro[4.5]decan-1-one Chemical compound CCS(=O)(=O)N1CCC2(C[C@@H](CCN3CCN(CC3)c3ccc(C)cc3)OC2=O)CC1 LTLWVHRDJYSFHE-OAQYLSRUSA-N 0.000 claims description 6
- IONUVCVGGHEYJY-LJQANCHMSA-N (3S)-8-methylsulfonyl-3-[2-[4-(4-nitrophenyl)piperazin-1-yl]ethyl]-2-oxa-8-azaspiro[4.5]decan-1-one Chemical compound CS(=O)(=O)N1CCC2(C[C@H](OC2=O)CCN2CCN(CC2)C2=CC=C(C=C2)[N+](=O)[O-])CC1 IONUVCVGGHEYJY-LJQANCHMSA-N 0.000 claims description 6
- KXRIRKPVAAHACV-HXUWFJFHSA-N (3S)-N-methyl-3-[2-[4-(4-methylphenyl)piperazin-1-yl]ethyl]-1-oxo-2-oxa-8-azaspiro[4.5]decane-8-carboxamide Chemical compound CNC(=O)N1CCC2(C[C@H](OC2=O)CCN2CCN(CC2)C2=CC=C(C=C2)C)CC1 KXRIRKPVAAHACV-HXUWFJFHSA-N 0.000 claims description 6
- 102100039126 5-hydroxytryptamine receptor 7 Human genes 0.000 claims description 6
- 101710150237 5-hydroxytryptamine receptor 7 Proteins 0.000 claims description 6
- 125000003118 aryl group Chemical group 0.000 claims description 6
- 230000008482 dysregulation Effects 0.000 claims description 6
- 230000000694 effects Effects 0.000 claims description 6
- VOJBZZBHLSTQEF-FQEVSTJZSA-N methyl (3R)-3-[2-[4-(4-methylphenyl)piperazin-1-yl]ethyl]-1-oxo-2-oxa-8-azaspiro[4.5]decane-8-carboxylate Chemical compound O=C1O[C@H](CC11CCN(CC1)C(=O)OC)CCN1CCN(CC1)C1=CC=C(C=C1)C VOJBZZBHLSTQEF-FQEVSTJZSA-N 0.000 claims description 6
- VOJBZZBHLSTQEF-HXUWFJFHSA-N methyl (3S)-3-[2-[4-(4-methylphenyl)piperazin-1-yl]ethyl]-1-oxo-2-oxa-8-azaspiro[4.5]decane-8-carboxylate Chemical compound COC(=O)N1CCC2(C[C@@H](CCN3CCN(CC3)c3ccc(C)cc3)OC2=O)CC1 VOJBZZBHLSTQEF-HXUWFJFHSA-N 0.000 claims description 6
- 201000000980 schizophrenia Diseases 0.000 claims description 6
- LUUITHOAXYRRNW-QFIPXVFZSA-N tert-butyl (3R)-1-oxo-3-[2-[4-(2-propan-2-ylphenyl)piperazin-1-yl]ethyl]-2-oxa-8-azaspiro[4.5]decane-8-carboxylate Chemical compound C(C)(C)C1=C(C=CC=C1)N1CCN(CC1)CC[C@@H]1OC(C2(C1)CCN(CC2)C(=O)OC(C)(C)C)=O LUUITHOAXYRRNW-QFIPXVFZSA-N 0.000 claims description 6
- RLBLOGNCSXWQGN-FQEVSTJZSA-N tert-butyl (3R)-3-[2-(3,4-dihydro-1H-isoquinolin-2-yl)ethyl]-1-oxo-2-oxa-8-azaspiro[4.5]decane-8-carboxylate Chemical compound C1N(CCC2=CC=CC=C12)CC[C@@H]1OC(C2(C1)CCN(CC2)C(=O)OC(C)(C)C)=O RLBLOGNCSXWQGN-FQEVSTJZSA-N 0.000 claims description 6
- OFYTYDVDQKSHCN-FQEVSTJZSA-N tert-butyl (3R)-3-[2-[4-(2-methyl-1H-benzimidazol-4-yl)piperazin-1-yl]ethyl]-1-oxo-2-oxa-8-azaspiro[4.5]decane-8-carboxylate Chemical compound CC1=NC2=C(N1)C(=CC=C2)N1CCN(CC1)CC[C@@H]1OC(C2(C1)CCN(CC2)C(=O)OC(C)(C)C)=O OFYTYDVDQKSHCN-FQEVSTJZSA-N 0.000 claims description 6
- LUUITHOAXYRRNW-JOCHJYFZSA-N tert-butyl (3S)-1-oxo-3-[2-[4-(2-propan-2-ylphenyl)piperazin-1-yl]ethyl]-2-oxa-8-azaspiro[4.5]decane-8-carboxylate Chemical compound C(C)(C)C1=C(C=CC=C1)N1CCN(CC1)CC[C@H]1OC(C2(C1)CCN(CC2)C(=O)OC(C)(C)C)=O LUUITHOAXYRRNW-JOCHJYFZSA-N 0.000 claims description 6
- RLBLOGNCSXWQGN-HXUWFJFHSA-N tert-butyl (3S)-3-[2-(3,4-dihydro-1H-isoquinolin-2-yl)ethyl]-1-oxo-2-oxa-8-azaspiro[4.5]decane-8-carboxylate Chemical compound C1N(CCC2=CC=CC=C12)CC[C@H]1OC(C2(C1)CCN(CC2)C(=O)OC(C)(C)C)=O RLBLOGNCSXWQGN-HXUWFJFHSA-N 0.000 claims description 6
- VJBPXHGLMVAHSC-JOCHJYFZSA-N (3S)-3-[2-[4-(4-methylphenyl)piperazin-1-yl]ethyl]-8-(1-methylpyrazol-4-yl)sulfonyl-2-oxa-8-azaspiro[4.5]decan-1-one Chemical compound CN1N=CC(=C1)S(=O)(=O)N1CCC2(C[C@H](OC2=O)CCN2CCN(CC2)C2=CC=C(C=C2)C)CC1 VJBPXHGLMVAHSC-JOCHJYFZSA-N 0.000 claims description 4
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims description 4
- 208000020925 Bipolar disease Diseases 0.000 claims description 4
- 208000017164 Chronobiology disease Diseases 0.000 claims description 4
- 206010020772 Hypertension Diseases 0.000 claims description 4
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 4
- 208000026139 Memory disease Diseases 0.000 claims description 4
- 208000019695 Migraine disease Diseases 0.000 claims description 4
- 208000007920 Neurogenic Inflammation Diseases 0.000 claims description 4
- 208000018262 Peripheral vascular disease Diseases 0.000 claims description 4
- 208000027030 Premenstrual dysphoric disease Diseases 0.000 claims description 4
- 206010036618 Premenstrual syndrome Diseases 0.000 claims description 4
- 208000029061 Temperature regulation disease Diseases 0.000 claims description 4
- 125000003545 alkoxy group Chemical group 0.000 claims description 4
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims description 4
- 230000000971 hippocampal effect Effects 0.000 claims description 4
- 201000003723 learning disability Diseases 0.000 claims description 4
- 206010027599 migraine Diseases 0.000 claims description 4
- 210000005036 nerve Anatomy 0.000 claims description 4
- 230000002093 peripheral effect Effects 0.000 claims description 4
- 208000022821 personality disease Diseases 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 230000002028 premature Effects 0.000 claims description 4
- 208000019116 sleep disease Diseases 0.000 claims description 4
- 208000020685 sleep-wake disease Diseases 0.000 claims description 4
- 125000000000 cycloalkoxy group Chemical group 0.000 claims description 2
- 125000004438 haloalkoxy group Chemical group 0.000 claims description 2
- 229910052736 halogen Inorganic materials 0.000 claims description 2
- 150000002367 halogens Chemical class 0.000 claims description 2
- 229910052760 oxygen Inorganic materials 0.000 claims description 2
- 229910052717 sulfur Inorganic materials 0.000 claims description 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 10
- LWWQWOBMASADIS-QFIPXVFZSA-N (3R)-3-[2-[4-(4-methylphenyl)piperazin-1-yl]ethyl]-8-propylsulfonyl-2-oxa-8-azaspiro[4.5]decan-1-one Chemical compound C(CC)S(=O)(=O)N1CCC2(C[C@@H](OC2=O)CCN2CCN(CC2)C2=CC=C(C=C2)C)CC1 LWWQWOBMASADIS-QFIPXVFZSA-N 0.000 claims 3
- FQKXMSNIIBZBSZ-OAQYLSRUSA-N (3S)-8-(1H-imidazol-5-ylsulfonyl)-3-[2-[4-(4-methylphenyl)piperazin-1-yl]ethyl]-2-oxa-8-azaspiro[4.5]decan-1-one Chemical compound N1C=NC(=C1)S(=O)(=O)N1CCC2(C[C@H](OC2=O)CCN2CCN(CC2)C2=CC=C(C=C2)C)CC1 FQKXMSNIIBZBSZ-OAQYLSRUSA-N 0.000 claims 3
- WSHWGBBKHQGSRE-NRFANRHFSA-N 2-[[(3R)-3-[2-[4-(4-methylphenyl)piperazin-1-yl]ethyl]-1-oxo-2-oxa-8-azaspiro[4.5]decan-8-yl]sulfonyl]acetonitrile Chemical compound O=C1O[C@H](CC11CCN(CC1)S(=O)(=O)CC#N)CCN1CCN(CC1)C1=CC=C(C=C1)C WSHWGBBKHQGSRE-NRFANRHFSA-N 0.000 claims 3
- WSHWGBBKHQGSRE-OAQYLSRUSA-N 2-[[(3S)-3-[2-[4-(4-methylphenyl)piperazin-1-yl]ethyl]-1-oxo-2-oxa-8-azaspiro[4.5]decan-8-yl]sulfonyl]acetonitrile Chemical compound O=C1O[C@@H](CC11CCN(CC1)S(=O)(=O)CC#N)CCN1CCN(CC1)C1=CC=C(C=C1)C WSHWGBBKHQGSRE-OAQYLSRUSA-N 0.000 claims 3
- COMNXBZKDGZNBB-UHFFFAOYSA-N 3-[2-[4-(4-methylphenyl)piperazin-1-yl]ethyl]-8-(trifluoromethylsulfonyl)-2-oxa-8-azaspiro[4.5]decan-1-one Chemical compound C1(=CC=C(C=C1)N1CCN(CC1)CCC1OC(C2(C1)CCN(CC2)S(=O)(=O)C(F)(F)F)=O)C COMNXBZKDGZNBB-UHFFFAOYSA-N 0.000 claims 3
- 206010013887 Dysarthria Diseases 0.000 claims 2
- 208000019454 Feeding and Eating disease Diseases 0.000 claims 2
- 208000022804 avoidant personality disease Diseases 0.000 claims 2
- 208000012672 seasonal affective disease Diseases 0.000 claims 2
- 230000011664 signaling Effects 0.000 claims 2
- 0 CC*(CC(C)(C)*)C(CC1(CC)C*C)OC1=O Chemical compound CC*(CC(C)(C)*)C(CC1(CC)C*C)OC1=O 0.000 description 82
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 18
- 238000000034 method Methods 0.000 description 7
- COMNXBZKDGZNBB-IBGZPJMESA-N (3R)-3-[2-[4-(4-methylphenyl)piperazin-1-yl]ethyl]-8-(trifluoromethylsulfonyl)-2-oxa-8-azaspiro[4.5]decan-1-one Chemical compound C1(=CC=C(C=C1)N1CCN(CC1)CC[C@@H]1OC(C2(C1)CCN(CC2)S(=O)(=O)C(F)(F)F)=O)C COMNXBZKDGZNBB-IBGZPJMESA-N 0.000 description 3
- AOQMTPLAFACCAA-UHFFFAOYSA-N 3-[2-[4-(4-methylphenyl)piperazin-1-yl]ethyl]-2-oxa-8-azaspiro[4.5]decan-1-one Chemical compound C1(=CC=C(C=C1)N1CCN(CC1)CCC1OC(C2(C1)CCNCC2)=O)C AOQMTPLAFACCAA-UHFFFAOYSA-N 0.000 description 3
- 208000027534 Emotional disease Diseases 0.000 description 2
- 230000001932 seasonal effect Effects 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022113079A JP7482948B2 (ja) | 2016-11-15 | 2022-07-14 | ５－ヒドロキシトリプタミン受容体７の新規調節因子およびその使用方法 |
| JP2024073922A JP2024091996A (ja) | 2016-11-15 | 2024-04-30 | ５－ヒドロキシトリプタミン受容体７の新規調節因子およびその使用方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662422344P | 2016-11-15 | 2016-11-15 | |
| US62/422,344 | 2016-11-15 | ||
| PCT/US2017/061677 WO2018093818A1 (en) | 2016-11-15 | 2017-11-15 | Novel modulators of the 5-hydroxytryptamine receptor 7 and their method of use |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022113079A Division JP7482948B2 (ja) | 2016-11-15 | 2022-07-14 | ５－ヒドロキシトリプタミン受容体７の新規調節因子およびその使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019535825A JP2019535825A (ja) | 2019-12-12 |
| JP2019535825A5 true JP2019535825A5 (enExample) | 2020-12-24 |
| JP7107955B2 JP7107955B2 (ja) | 2022-07-27 |
Family
ID=62146107
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019547227A Active JP7107955B2 (ja) | 2016-11-15 | 2017-11-15 | ５－ヒドロキシトリプタミン受容体７の新規調節因子およびその使用方法 |
| JP2022113079A Active JP7482948B2 (ja) | 2016-11-15 | 2022-07-14 | ５－ヒドロキシトリプタミン受容体７の新規調節因子およびその使用方法 |
| JP2024073922A Pending JP2024091996A (ja) | 2016-11-15 | 2024-04-30 | ５－ヒドロキシトリプタミン受容体７の新規調節因子およびその使用方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022113079A Active JP7482948B2 (ja) | 2016-11-15 | 2022-07-14 | ５－ヒドロキシトリプタミン受容体７の新規調節因子およびその使用方法 |
| JP2024073922A Pending JP2024091996A (ja) | 2016-11-15 | 2024-04-30 | ５－ヒドロキシトリプタミン受容体７の新規調節因子およびその使用方法 |
Country Status (14)
| Country | Link |
|---|---|
| US (4) | US10858368B2 (enExample) |
| EP (1) | EP3541790B1 (enExample) |
| JP (3) | JP7107955B2 (enExample) |
| KR (1) | KR102590403B1 (enExample) |
| CN (2) | CN110177776B (enExample) |
| AU (3) | AU2017361078B2 (enExample) |
| CA (1) | CA3043319A1 (enExample) |
| CL (1) | CL2019001329A1 (enExample) |
| EA (1) | EA201990915A1 (enExample) |
| IL (3) | IL291029B2 (enExample) |
| MX (2) | MX394746B (enExample) |
| UA (1) | UA125631C2 (enExample) |
| WO (1) | WO2018093818A1 (enExample) |
| ZA (1) | ZA202105774B (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2970223B1 (en) | 2013-03-11 | 2020-04-15 | Temple University Of The Commonwealth System Of Higher Education | Novel 5-hydroxytryptamine receptor 7 activity modulators and their method of use |
| WO2016040554A1 (en) | 2014-09-10 | 2016-03-17 | Temple University-Of The Commonwealth System Of Higher Education | Novel 5-hydroxytryptamine receptor 7 activity modulators and their method of use |
| WO2018093818A1 (en) | 2016-11-15 | 2018-05-24 | Temple University-Of The Commonwealth System Of Higher Education | Novel modulators of the 5-hydroxytryptamine receptor 7 and their method of use |
| EP3600289A4 (en) | 2017-03-21 | 2020-08-05 | Temple University - Of The Commonwealth System of Higher Education | 5-HYDROXYTRYPTAMINE RECEPTOR 7 MODULATORS AND THE USE OF THESE AS THERAPEUTIC AGENTS |
| EP3600290B1 (en) * | 2017-03-21 | 2025-06-04 | Temple University - Of The Commonwealth System of Higher Education | Novel modulators of the sigma-2 receptor and their method of use |
| KR20210020182A (ko) * | 2018-05-11 | 2021-02-23 | 템플 유니버시티-오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 | 5-히드록시트립타민 수용체 7의 조절자로서의 신규한 기능화된 락탐 및 이의 사용 방법 |
| WO2021097116A1 (en) * | 2019-11-13 | 2021-05-20 | Temple University-Of The Commonwealth System Of Higher Education | Novel functionalized lactams as modulators of the 5-hydroxytryptamine receptor 7 and their method of use |
| MX2022005819A (es) * | 2019-11-13 | 2022-08-16 | Univ Temple | Nuevas lactonas funcionalizadas como moduladores del receptor 7 de 5-hidroxitriptamina y su método de uso. |
| TW202328148A (zh) * | 2021-09-22 | 2023-07-16 | 日商塩野義製藥股份有限公司 | 具有血清素受體結合活性之螺雜環衍生物 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040064499A1 (en) | 2002-09-26 | 2004-04-01 | Kasra Kasravi | Method and system for active knowledge management |
| EP1592772A2 (en) | 2003-01-31 | 2005-11-09 | Pfizer Products Incorporated | 5ht7 antagonists and inverse agonists |
| BRPI0506909A (pt) * | 2004-01-16 | 2007-05-29 | Hoffmann La Roche | derivados de 1-benzil-5piperazin-1-il-3,4 diidro-1h-quinazolin-2-ona e os respectivos derivados de 1h-benzo (1,2,6) tiadiazina-2,2-dióxido e 1,4-diidro-benzo (d) (1,3)oxazin-2-ona como moduladores do receptor de 5-hidroxitriptamina (5-ht) para o tratamento de doenças do sistema nervoso central |
| BRPI0614397A2 (pt) * | 2005-08-04 | 2011-03-29 | Janssen Pharmaceutica Nv | compostos de pirimidina como moduladores de receptor de serotonina |
| EP1875899A1 (en) | 2006-06-29 | 2008-01-09 | Laboratorios Del Dr. Esteve, S.A. | Use of 5HT7 receptor agonists for the treatment of pain |
| ES2380756T3 (es) | 2007-10-12 | 2012-05-18 | Eli Lilly And Company | Antagonistas del receptor 5-HT7 |
| US7902091B2 (en) | 2008-08-13 | 2011-03-08 | Varian Semiconductor Equipment Associates, Inc. | Cleaving of substrates |
| CA2735934C (en) | 2008-09-05 | 2014-01-07 | Supernus Pharmaceuticals, Inc. | Method of treatment of attention deficit/hyperactivity disorder (adhd) |
| WO2010069390A1 (en) | 2008-12-19 | 2010-06-24 | Nokia Siemens Networks Oy | Method and device for data processing in an udwdm network and communication system comprising such device |
| US8637263B1 (en) * | 2010-10-14 | 2014-01-28 | Epiomed Therapeutics, Inc. | Assay for determination of compounds having anti-emetic activity |
| WO2012058769A1 (en) | 2010-11-03 | 2012-05-10 | Mcmaster University | Method of treating mucosal inflammation |
| WO2013154513A1 (en) * | 2012-04-04 | 2013-10-17 | Mi̇lli̇ Savunma Bakanliği | The use of 5-ht7 receptor antagonists including some atypical antipsychotics as antipruritic agents |
| US9464062B2 (en) | 2012-11-28 | 2016-10-11 | Temple University—Of the Commonwealth System of Higher Education | Disubstituted oxazolidin-2-ones 5-hydroxytryptamine receptor 2B activity modulators |
| EP2970223B1 (en) * | 2013-03-11 | 2020-04-15 | Temple University Of The Commonwealth System Of Higher Education | Novel 5-hydroxytryptamine receptor 7 activity modulators and their method of use |
| WO2016040554A1 (en) * | 2014-09-10 | 2016-03-17 | Temple University-Of The Commonwealth System Of Higher Education | Novel 5-hydroxytryptamine receptor 7 activity modulators and their method of use |
| US20180221365A1 (en) | 2015-05-12 | 2018-08-09 | Temple University-Of The Commonwealth System Of Higher Education | Novel sigma-2 receptor binders and their method of use |
| WO2018093818A1 (en) | 2016-11-15 | 2018-05-24 | Temple University-Of The Commonwealth System Of Higher Education | Novel modulators of the 5-hydroxytryptamine receptor 7 and their method of use |
| EP3600289A4 (en) | 2017-03-21 | 2020-08-05 | Temple University - Of The Commonwealth System of Higher Education | 5-HYDROXYTRYPTAMINE RECEPTOR 7 MODULATORS AND THE USE OF THESE AS THERAPEUTIC AGENTS |
| EP3600290B1 (en) | 2017-03-21 | 2025-06-04 | Temple University - Of The Commonwealth System of Higher Education | Novel modulators of the sigma-2 receptor and their method of use |
| KR20210020182A (ko) | 2018-05-11 | 2021-02-23 | 템플 유니버시티-오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 | 5-히드록시트립타민 수용체 7의 조절자로서의 신규한 기능화된 락탐 및 이의 사용 방법 |
| MX2022005819A (es) * | 2019-11-13 | 2022-08-16 | Univ Temple | Nuevas lactonas funcionalizadas como moduladores del receptor 7 de 5-hidroxitriptamina y su método de uso. |
-
2017
- 2017-11-15 WO PCT/US2017/061677 patent/WO2018093818A1/en not_active Ceased
- 2017-11-15 UA UAA201906703A patent/UA125631C2/uk unknown
- 2017-11-15 CN CN201780079945.9A patent/CN110177776B/zh active Active
- 2017-11-15 IL IL291029A patent/IL291029B2/en unknown
- 2017-11-15 AU AU2017361078A patent/AU2017361078B2/en active Active
- 2017-11-15 MX MX2019005603A patent/MX394746B/es unknown
- 2017-11-15 JP JP2019547227A patent/JP7107955B2/ja active Active
- 2017-11-15 CN CN202510142805.8A patent/CN119977980A/zh active Pending
- 2017-11-15 US US16/349,811 patent/US10858368B2/en active Active
- 2017-11-15 EA EA201990915A patent/EA201990915A1/ru unknown
- 2017-11-15 KR KR1020197016744A patent/KR102590403B1/ko active Active
- 2017-11-15 EP EP17871446.5A patent/EP3541790B1/en active Active
- 2017-11-15 CA CA3043319A patent/CA3043319A1/en active Pending
- 2017-11-15 IL IL309982A patent/IL309982A/en unknown
-
2019
- 2019-05-06 IL IL266483A patent/IL266483B/en unknown
- 2019-05-14 MX MX2022009907A patent/MX2022009907A/es unknown
- 2019-05-15 CL CL2019001329A patent/CL2019001329A1/es unknown
-
2020
- 2020-09-09 US US17/015,696 patent/US11319327B2/en active Active
-
2021
- 2021-08-13 ZA ZA2021/05774A patent/ZA202105774B/en unknown
-
2022
- 2022-03-31 US US17/709,847 patent/US12338247B2/en active Active
- 2022-04-04 AU AU2022202240A patent/AU2022202240B2/en active Active
- 2022-07-14 JP JP2022113079A patent/JP7482948B2/ja active Active
-
2024
- 2024-04-30 JP JP2024073922A patent/JP2024091996A/ja active Pending
- 2024-06-20 AU AU2024204240A patent/AU2024204240A1/en active Pending
-
2025
- 2025-05-20 US US19/213,974 patent/US20250282790A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019535825A5 (enExample) | ||
| TWI500616B (zh) | 新穎之雙環吡啶酮 | |
| US10131669B2 (en) | Pyrazolopyrimidine compounds | |
| JP6506833B2 (ja) | イミダゾピリダジン化合物 | |
| TWI568733B (zh) | 新穎的唏及１，１ａ，２，７ｂ－四氫環丙烷［ｃ］唏吡啶并吡化合物 | |
| AU2015341913A1 (en) | Pharmaceutical compound | |
| RU2009103307A (ru) | ПРОИЗВОДНЫЕ ИМИДАЗО[1, 2-a]ПИРИДИН-2-КАРБОКСАМИДОВ, ИХ ПОЛУЧЕНИЕ И ПРИМЕНЕНИЕ В ТЕРАПИИ | |
| JP2020511515A5 (enExample) | ||
| TW201443048A (zh) | 氮雜苯并咪唑化合物 | |
| JP2020502092A5 (enExample) | ||
| JP2010521528A (ja) | Ｃｎｓ活性化合物としてのインドリジン及びそのアザ類似誘導体 | |
| RU2010119560A (ru) | Замещенные n-фенилбипирролидинкарбоксамиды и их терапевтическое применение | |
| CN106061964A (zh) | 能够刺激神经发生的n‑苯基‑内酰胺衍生物及其在神经性病症的治疗中的用途 | |
| JP6628805B2 (ja) | 新規シクロプロパベンゾフラニルピリドピラジンジオン | |
| JP2020502089A (ja) | 化合物、組成物および方法 | |
| RU2016104890A (ru) | Производные 1,7-нафтиридина | |
| JP2016525142A5 (enExample) | ||
| JP2016531880A (ja) | ガンマセクレターゼモジュレーターとしての新規二環式ピリジノン | |
| KR102148587B1 (ko) | 6,7-디히드로-5H-피라졸로[5,1-b][1,3]옥사진-2-카르복스아미드 화합물 | |
| JP2006516626A5 (enExample) | ||
| JP2018522915A5 (enExample) | ||
| JP2019535715A5 (enExample) | ||
| JP2015513521A5 (enExample) | ||
| JP2022151801A (ja) | 複素環化合物 | |
| KR20250121123A (ko) | 치환된 테트라히드로피롤로-피리디논 화합물 및 의학적 병태를 치료하는 데 있어서의 이의 용도 |